Thomas FitzGerald to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Thomas FitzGerald has written about Randomized Controlled Trials as Topic.
Connection Strength
0.082
-
Varlotto JM, Sun Z, Ky B, Upshaw J, Fitzgerald TJ, Diehn M, Lovly C, Belani C, Oettel K, Masters G, Harkenrider M, Ross H, Ramalingam S, Pennell NA. A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. Clin Lung Cancer. 2022 11; 23(7):547-560.
Score: 0.038
-
Varlotto JM, Sun Z, Ky B, Upshaw J, Katz SI, Fitzgerald TJ, Wakelee H, Diehn M, Mankoff DA, Lovely C, Belani C, Oettel K, Masters G, Ramalingam S, Pennell NA. A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist. 2021 06; 26(6):523-532.
Score: 0.035
-
Raney RB, Meza J, Anderson JR, Fryer CJ, Donaldson SS, Breneman JC, Fitzgerald TJ, Gehan EA, Michalski JM, Ortega JA, Qualman SJ, Sandler E, Wharam MD, Wiener ES, Maurer HM, Crist WM. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol. 2002 Jan; 38(1):22-32.
Score: 0.009